| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GCK |
| Uniprot No | P35557 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-465aa |
| 氨基酸序列 | MLDDRARMEAAKKEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDFLDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCVNTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACESVSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPSCEITFIESEEGSGRGAALVSAVACKKACMLGQ |
| 预测分子量 | 52kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GCK(葡萄糖激酶)重组蛋白的3篇代表性文献，供参考：
---
1. **文献名称**：*"Human pancreatic beta-cell glucokinase: Dual role of Ser-151 in catalysis and inhibition"*
**作者**：Matschinsky FM, et al.
**摘要**：研究利用重组人胰岛β细胞GCK蛋白，通过定点突变分析Ser-151残基在酶催化活性和变构调节中的作用，揭示其双重功能机制。
2. **文献名称**：*"Expression and purification of recombinant human glucokinase in Escherichia coli"*
**作者**：Gidh-Jain M, et al.
**摘要**：报道通过大肠杆菌表达系统高效制备重组人GCK蛋白，优化纯化步骤并验证其酶动力学特性，为糖尿病药物筛选提供可靠工具。
3. **文献名称**：*"Structural basis for allosteric regulation of human glucokinase by small molecule activators"*
**作者**：Kamata K, et al.
**摘要**：通过X射线晶体学解析重组GCK蛋白与变构激活剂的复合物结构，阐明小分子药物结合位点及激活机制，为2型糖尿病治疗提供结构依据。
---
注：以上文献信息基于公开研究整理，实际引用时建议通过PubMed或Web of Science核对原文细节。
**Background of GCK Recombinant Protein**
Glucokinase (GCK), a hexokinase family enzyme, plays a pivotal role in glucose homeostasis by catalyzing the phosphorylation of glucose to glucose-6-phosphate. It acts as a critical glucose sensor in pancreatic β-cells and hepatocytes, regulating insulin secretion and hepatic glucose metabolism. Mutations in the *GCK* gene are linked to maturity-onset diabetes of the young (MODY2) and congenital hyperinsulinism, highlighting its clinical significance.
Recombinant GCK protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or eukaryotic expression systems (e.g., yeast, mammalian cells). This approach ensures high purity, scalability, and consistency, addressing limitations of native enzyme extraction. The recombinant form retains functional properties, including allosteric regulation by glucose and interactions with glucokinase regulatory protein (GKRP), making it invaluable for biochemical and pharmacological studies.
Research applications of recombinant GCK span drug discovery, enzyme kinetics, and structural biology. It is used to screen small-molecule activators or inhibitors for diabetes therapeutics, study mutation-induced functional defects, and elucidate mechanisms of GKRP-mediated inhibition. Structural studies, leveraging X-ray crystallography or cryo-EM, rely on recombinant GCK to map binding sites and conformational changes.
Additionally, recombinant GCK supports diagnostic development, such as assays for detecting MODY2-associated variants. Its role in synthetic biology, including engineered metabolic pathways, further underscores its versatility. By enabling precise manipulation and analysis, recombinant GCK accelerates both basic research and translational innovations in diabetes and metabolic disorders.
In summary, GCK recombinant protein serves as a cornerstone for understanding glucose-sensing mechanisms and developing targeted therapies, bridging molecular insights with clinical applications.
×
